Free Trial
NASDAQ:TLSI

TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

TriSalus Life Sciences logo
$4.78 +0.15 (+3.24%)
Closing price 04:00 PM Eastern
Extended Trading
$4.77 -0.01 (-0.21%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TriSalus Life Sciences Stock (NASDAQ:TLSI)

Advanced

Key Stats

Today's Range
$4.57
$4.80
50-Day Range
$3.57
$5.22
52-Week Range
$3.42
$5.88
Volume
181,419 shs
Average Volume
72,667 shs
Market Capitalization
$238.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.90
Consensus Rating
Buy

Company Overview

TriSalus Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

TLSI MarketRank™: 

TriSalus Life Sciences scored higher than 42% of companies evaluated by MarketBeat, and ranked 677th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    TriSalus Life Sciences has a consensus price target of $10.90, representing about 128.0% upside from its current price of $4.78.

  • Amount of Analyst Coverage

    TriSalus Life Sciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about TriSalus Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TriSalus Life Sciences is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TriSalus Life Sciences is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about TriSalus Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.19% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    TriSalus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    TriSalus Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.19% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    3 people have searched for TLSI on MarketBeat in the last 30 days.
  • MarketBeat Follows

    3 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.50% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.58% of the stock of TriSalus Life Sciences is held by institutions.

  • Read more about TriSalus Life Sciences' insider trading history.
Receive TLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TLSI Stock News Headlines

TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen
URGENT: The Market's 3 Red Flags Are Flashing
Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends.tc pixel
See More Headlines

TLSI Stock Analysis - Frequently Asked Questions

TriSalus Life Sciences' stock was trading at $5.01 at the beginning of the year. Since then, TLSI shares have decreased by 4.6% and is now trading at $4.78.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.05. The firm earned $11.21 million during the quarter, compared to analysts' expectations of $10.69 million.
Read the conference call transcript
.

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB).

Company Calendar

Last Earnings
8/12/2025
Today
10/07/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TLSI
Previous Symbol
NASDAQ:TLSI
CIK
1826667
Fax
N/A
Employees
106
Year Founded
2009

Price Target and Rating

High Price Target
$12.50
Low Price Target
$10.00
Potential Upside/Downside
+135.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.05 million
Net Margins
-86.61%
Pretax Margin
-86.61%
Return on Equity
N/A
Return on Assets
-116.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.08
Quick Ratio
3.68

Sales & Book Value

Annual Sales
$29.43 million
Price / Sales
7.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.83) per share
Price / Book
-5.58

Miscellaneous

Outstanding Shares
49,870,000
Free Float
36,154,000
Market Cap
$230.90 million
Optionable
Not Optionable
Beta
0.47

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:TLSI) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners